Drug Profile
Research programme: antibacterials - Millennium/Wyeth
Alternative Names: Antibacterials research programme - Millennium/WyethLatest Information Update: 22 Mar 2002
Price :
$50
*
At a glance
- Originator Millennium Pharmaceuticals; Wyeth
- Developer Millennium Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 22 Mar 2002 Discontinued - Preclinical for Bacterial infections in USA (unspecified route)
- 15 Jan 2001 Millennium and Wyeth-Ayerst identify preclinical antibacterial compound
- 11 Jan 2000 New profile